
Market close: NZ stocks buckle, sink to lowest point for 2023
Comments from the US Fed did little to alleviate fears.
Comments from the US Fed did little to alleviate fears.
The S&P/NZX50 index was at 11,135.58, down 85.90 points or 0.77 per cent.
The S&P/NZX 50 Index edged up 0.06 per cent.
The S&P/NZX 50 Index edged up 0.26 per cent.
Fletcher Building resumed trading today after being in a halt since Wednesday.
OPINION: Investors should take a safety-first approach and avoid making rash decisions.
New Zealand's sharemarket ended weaker despite a rally in Sky TV.
The S&P/NZX 50 Index rose 13.1 points, or 0.12 per cent.
International funds coming in helped propel the local market.
It’s not just pre-election jitters that are bleeding into the quiet market.
Will the Reserve Bank of New Zealand follow the RBA's line of thinking – or go rogue?
The company is waiting for its medicinal cannabis products to be verified.
No reason for optimism as we enter 'bear killer' month.
Some dairy gains expected - but is the futures market pricing overcooked?
The S&P/NZX50 Index fell by more than 1 per cent.
Watchdog says it's more important that Fonterra is the processor of choice.
The NZ sharemarket was down as investors press pause.
New Zealand’s benchmark share index edged slightly higher.
The retailer had its first year of “uninterrupted trade” post-pandemic.
Prices for several crucial exports up again at latest auction.
Elsewhere in the markets, Synlait bounced back after a big fall yesterday.
A2 Milk wants to cancel Synlait’s exclusive milk formula production and supply deal.
Fish n' chip shop became a major company. Now Sealord wants it.
Yesterday's half a per cent gain is all but forgotten.
The New Zealand sharemarket broke a sequence of down days.
The index has fallen in eight of the last nine trading days.
GLP-1 has been wreaking havoc on healthcare stocks around the world.
An investigation has outlined the damage and cause of a devastating car yard fire.
Potential Canadian raider says it won't participate.
Weight-loss drugs could beef up Big Pharma's bottom line.